PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Depression

Oncology NEWS International. Vol. 11 No. 9
Pages: 1  2  3  
Next
 

Panel Urges Control of Cancer-Related Pain, Depression, Fatigue

September 1, 2002

BETHESDA, Maryland—Labeling the treatment of pain, depression, and fatigue in many cancer patients inadequate, a National Institutes of Health (NIH) state-of-the-science panel has called for optimal symptom control for all cancer patients from diagnosis and throughout their illness. It also called for escalated funding to support research on the definition, occurrence, assessment, and treatment of all three problems.

"Currently, cancer-related pain, depression, and fatigue are undertreated, and this situation is simply unacceptable," said chair Donald L. Patrick, PhD, MSPH, professor and director of the Social and Behavioral Sciences Program, Department of Health Services, University of Washington, Seattle. "There are effective strategies to manage these symptoms, and all patients should have optimal symptom control."

The 13-member panel spent 2 days listening to expert testimony and drafting a statement. It released its final report on the third day of the conference after hearing public comments on the draft. Although sponsored by the National Cancer Institute and NIH’s Office of Medical Applications of Research, and co-sponsored by six other NIH units and the FDA, the panel was an independent body, and its statement does not represent NIH or federal policy.

In its report, the panel addressed five issues—occurrence, the reliability and validity of methods for clinical assessment, the effectiveness of treatments, impediments to effective symptom management, and future directions for research.

With regard to the occurrence of pain, depression, and fatigue, "published studies on all three symptoms are virtually restricted to prevalence data; there are no reliable incidence studies," the report said. Prevalence studies estimate a range of 14% to 100% for pain, 1% to 42% for depression, and 4% to 91% for fatigue. The estimates’ lack of consistency stems from both conceptualization and measurement problems, and weaknesses in research methodology, the panel said.

Assessment

Most clinical assessments of pain, depression, and fatigue rely on self-reporting by patients, who do the best job of assessing the severity of their own symptoms, but the sickest patients often cannot complete symptom questionnaires. Although a number of assessment tools exist, only a few assess all three symptoms simultaneously.

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
RELATED TOPICS

Bipolar disorder
Depressive disorders
Dysthymia
Mood disorders
Psychotic affective disorders
Major depressive disorder
Suicide prevention and assessment


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • The Moral Struggles of Practicing Psychiatrists
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Experts Discuss Changes, Updates in DSM-5
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • You Are—And Your Mood Is—What You Eat
  • Grief and Depression: The Sages Knew the Difference
  • Experts Discuss Changes, Updates in DSM-5
  • Developmental Psychopathology Comes of Age
  • The Psychiatrist and the Slot Machine
  • The Role of Biological Tests in Psychiatric Diagnosis
  • You Are—And Your Mood Is—What You Eat
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Grief and Depression: The Sages Knew the Difference
  • Psychiatry and the Myth of “Medicalization”
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • Experts Discuss Changes, Updates in DSM-5
  • The Role of Biological Tests in Psychiatric Diagnosis
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Refinements in ECT Techniques
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy